Volume 13 Supplement 1
A large family having Muckle Wells Syndrome
© Kilic and Cekic 2015
Published: 28 September 2015
CAPS is a rare autoinflammatory disease associated with mutations in the NLRP3 gene that result in overactivation of the inflammasome, increased secretion of IL-1beta and IL-18, and systemic inflammation. Mutations in the NLRP3 gene on chromosome 1q44 causes cryopyrinopathies. These are autosomal dominant disorders with varying penetrance, which may also present de novo. MWS is an intermediate phenotype characterized by chronic or intermittent episodes of fever, headache, urticarial rash, arthralgias or arthritis, CNS involvement, ocular disorders and progressive deafness. Treatment is based on IL-1 antagonism, which usually results in prompt clinical response and may prevent amyloidosis.
Here we present a family whose 11 members have similar symptoms. Clinical data is collected during the course of ongoing patient care.
We evaluated the clinical features of 11 patients who were referred to our center. The median age of the patients was 25 years (range: 9-65 years). The ratio of females /males was 1.2 (6/5). All patients had arthritis with exacerbation on exposure to cold and ocular involvement, mostly in the form of conjunctivitis and far less commonly uveitis, irideal synechiae, band keratopathy, cataract, and impaired vision. The median age of onset of arthritis was 7 years (2-30 y), the median age of onset of ocular involvement was 8 years (2-45 y). Hearing loss in 73.6% of patients was detected. The median age of onset of hearing loss was 15 years (12-63 y). All patient except one had urticarial rash. The median age of onset of urticarial rash was 8 years (7-30 y). Genetic testing for mutations of NLRP3 gene has not done yet.
Two patients were treated with canakunimab (Ilaris, Novartis, Switzerland) which is a human anti-IL-1 beta monoclonal antibody given by subcutaneous injections every 8 weeks (2mg/kg). Following canakunimab treatment, attacks of arthritis and urticaria are getting fully under control, advances in keratopathy and hearing loss could be partially controlled.
MWS is characterized by recurrent fever and urticarial rash, progressive sensorineural deafness and the development of secondary amyloidosis. Treatment is based on IL-1 antagonism, which usually results in prompt clinical response and may prevent amyloidosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.